|Abstract:||The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.|
|Inventor(s):||Batchelor; Kenneth William (Chapel Hill, NC), Frye; Stephen Vernon (Durham, NC), Dorsey, Jr.; George F. (Raleigh, NC), Mook, Jr.; Robert A. (Chapel Hill, NC)|
|Assignee:||Glaxo Wellcome Inc. (Research Triangle Park, NC)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Publication Date||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Poland||180002||Nov 30, 2000|
|Slovakia||34796||Jul 03, 1996|
|Hong Kong||1004334||Nov 20, 1998|
|Germany||69407978||Feb 19, 1998|
|European Patent Office||0719278||Jan 14, 1998||SPC/GB03/018||United Kingdom||<disabled>|
|This preview shows a limited data set|
Subscribe for full access
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.